AGS-16C3F
Phase 1Completed 1 views this week 0 watching💤 Quiet
Interest: 29/100
29
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Carcinoma, Renal Cell
Conditions
Carcinoma, Renal Cell, Renal Cell Carcinoma of Papillary Histology, Renal Cell Carcinoma With Clear Cell Histology, Renal Cell Carcinoma With Non-Clear Cell Histology
Trial Timeline
Jul 18, 2012 → Feb 21, 2017
NCT ID
NCT01672775About AGS-16C3F
AGS-16C3F is a phase 1 stage product being developed by Astellas Pharma for Carcinoma, Renal Cell. The current trial status is completed. This product is registered under clinical trial identifier NCT01672775. Target conditions include Carcinoma, Renal Cell, Renal Cell Carcinoma of Papillary Histology, Renal Cell Carcinoma With Clear Cell Histology.
What happened to similar drugs?
20 of 20 similar drugs in Carcinoma, Renal Cell were approved
Approved (20) Terminated (1) Active (0)
Hype Score Breakdown
Clinical
6
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT01672775 | Phase 1 | Completed |
Competing Products
20 competing products in Carcinoma, Renal Cell